GN-RESOUND
ReSound LiNX launches in global markets today as a revolutionary hearing aid capable of streaming high-quality stereo sound from an iPhone® , iPad® and iPod touch® without the need for an additional pendant-like device. Users can also customize their hearing experience through the ReSound Smart App™. ReSound LiNX advances a number of ReSound technologies which already lead the hearing aid industry. Among them:
- ReSound LiNX applies the latest and most advanced version of Surround Sound by ReSound™ – an integrated sound processing technology providing top-rated quality sound.
- ReSound LiNX is a Made for iPhone hearing aid that offers direct streaming of sound from iPhone, iPad and iPod touch, allowing wearers to utilize their hearing aids to talk on the phone and listen to music in high-quality stereo sound without the need for an additional remote control, accessory or pendant.
- The accompanying ReSound Smart App allows users to set preferred volume levels as well as treble/bass settings, and use geo-tagging to assign and adjust to the acoustics of frequently visited places like home, work, favorite restaurants and more. ReSound Smart™ also features a ‘Find My Hearing Aid’ function to help users pinpoint their hearing aids if misplaced.
- ReSound LiNX is the smallest wireless Receiver-in-the-Ear hearing aid brought to market by GN ReSound, yet powerful enough to address 90% of all hearing losses.
- GN ReSound’s unique 3rd generation 2.4 GHz wireless technology , based on the all new SmartRange™ chipset, is the foundation of this latest technological breakthrough. ReSound LiNX is the first hearing aid on the market to integrate SmartRange with Bluetooth® Smart technology.
This revolutionary advance in hearing aid technology is also available as Beltone First™, the sister brand of ReSound, both owned and operated by GN ReSound. ReSound LiNX and Beltone First™ will be available through a global network of hearing care professionals. Consumers can find more information about ReSound LiNX on resoundlinx.com . Consumers can find more information about Beltone First on beltone.com .
“We saw an opportunity to create the world’s best hearing aid by combining the capability of GN ReSound’s life-changing technologies with the compatibility and global prevalence of iPhone, iPad and iPod touch,” said GN ReSound CEO Lars Viksmoen. “We are committed to improving people’s lives through use of innovative technology and look forward to more people correcting their hearing with this new technology – a triumph in accessibility for the hearing impaired.”
It is this breakthrough technology in hearing aids which granted ReSound LiNX a 2014 Consumer Electronics Show Design and Engineering Award honoree in the Accessible and Universal Design product category.
About GN ReSound
GN ReSound is a leading international developer and manufacturer of advanced and innovative hearing healthcare solutions. It advances the wireless revolution with its unique 2.4 GHz and Bluetooth® Smart solutions. GN ReSound has reinvented the hearing system with its revolutionary ReSound LiNX and Beltone First hearing aids, and is driving and defining the future of hearing care.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140224005645/en/
Contact:
JOHN PROCTER,
+1-703-587-9967
jprocter(at)mcbeestrategic.com
or
MELINDA
BOISJOLIE,
+1-703-943-0670
mboisjolie(at)mcbeestrategic.com
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum